An ongoing dialogue on HIV/AIDS, infectious diseases,
January 20th, 2011
A New Antiretroviral Drug Class, and a Movie
In my email in-box today was a very odd press release, referring to this paper, just published in PLoS ONE. With the subject line, “Koronis – Clinical Trial Results Demonstrate Promise for First Non-suppressive HIV Drug,” it included the following information:
Recently published Phase 2a clinical trial results show that the frequency of specific, drug-induced mutations in the HIV genome can be significantly increased by administering KP-1461, a drug being developed by Koronis Pharmaceuticals based on its novel Viral Decay Acceleration (VDA) drug mechanism. Koronis is planning a follow-on Phase 2 trial to determine the treatment duration required to achieve a clinically meaningful decrease in a patient’s viral load.
First, you don’t want to be known as a “Non-suppressive HIV drug.” And second, while I get the premise that giving a drug that leads to mutations probably indicates some sort of selection pressure, it’s a long way from this observation to an actual antiviral agent.
But who knows? This may be the next great antiviral drug class, and the phrase “Viral Decay Acceleration” — with its faint echo of 1950s sci-fi movies — sounds incredibly cool. According to the company’s web site, VDA “exploits the strength of a virus – its high mutation rate – to target its collapse.”
So dim the lights, grab some popcorn, and watch the movie here.
FROM NEJM — Recent Infectious Disease Articles- Stability of Avian Influenza A(H5N1) Virus in Milk from Infected Cows and Virus-Spiked Milk December 4, 2025Highly pathogenic avian influenza A(H5N1) virus has spread among dairy cattle, with virus detected in milk samples. In this report, virus viability after cold storage or pasteurization is assessed.
- Updated Evidence for Covid-19, RSV, and Influenza Vaccines for 2025–2026 December 4, 2025Results from recently published, peer-reviewed studies support the safety and effectiveness of immunizations against Covid-19, RSV, and influenza.
- Glucocorticoids for Pneumonia in Africa — Old Therapy, New Context December 4, 2025The African continent is home to 1.55 billion people, one fifth of the world’s population, spread over an area larger than the United States, China, and India combined. The disease burden is enormous,1 and health care resources are severely constrained. In one multinational survey, one in eight hospitalized...
- The New U.S. Global Health Strategy — A Reset of America’s Health Cooperation December 4, 2025The U.S. administration recently unveiled its new approach to global health. A retreat from multilateralism, a geopolitical emphasis, and rushed transitions could threaten progress.
- Empyema Necessitans December 4, 2025A 66-year-old man presented with 2 weeks of shortness of breath and cough, 5 days of left flank pain, and 2 days of a rapidly expanding mass on his left side.
- Stability of Avian Influenza A(H5N1) Virus in Milk from Infected Cows and Virus-Spiked Milk December 4, 2025